A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma

This publication has 20 references indexed in Scilit:

• Metastasectomy
  British Journal of Surgery, 1992
• Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
  Annals of Surgery, 1989
• Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase
  Cancer, 1989
• Changing patterns in the treatment of rectal cancer
  British Journal of Surgery, 1989
• Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness.
  The Journal of Experimental Medicine, 1987
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Changing survival prospects in rectal carcinoma
  Diseases of the Colon & Rectum, 1986
• Survival of 727 patients with single carcinomas of the large bowel
  Diseases of the Colon & Rectum, 1984
• Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
  The Journal of Experimental Medicine, 1983
• Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
  Science, 1976